Начало › Рак на белия дроб с недребноклетъчен тип › Пенсилвания › Philadelphia
Клинични проучвания за Рак на белия дроб с недребноклетъчен тип в Philadelphia, PA
51 проучвания за Рак на белия дроб с недребноклетъчен тип търсят участници в обекти в и около Philadelphia (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Набиране на участнициФаза 3
- Thomas Jefferson University Hospital, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- Temple University Hospital, Philadelphia
- и още 5
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Набиране на участнициФаза 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Набиране на участнициФаза 1
- Exelixis Clinical Site #98, Philadelphia
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Набиране на участнициФаза 3
- Perelman Center for Advanced Medicine ( Site 3205), Philadelphia
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Набиране на участнициФаза 3
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Torresdale Hospital, Philadelphia
- Lankenau Medical Center, Wynnewood · на 7 мили
- и още 2
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 3
- Alliance Cancer Specialists, PC, Wynnewood · на 7 мили
- Consultants in Medical Oncology and Hematology, P.C., Broomall · на 10 мили
- Alliance Cancer Specialists, PC, Media · на 12 мили
- и още 1
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Набиране на участнициФаза 3
- Alliance Cancer Specialists - Media, Media · на 12 мили
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Набиране на участнициФаза 3
- Research Site, Philadelphia
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- University of Pennsylvania, Philadelphia
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Health Northeast, Philadelphia
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Набиране на участнициФаза 1
- Research Site, Philadelphia
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Набиране на участнициФаза 2
- Lankenau Medical Center, Wynnewood · на 7 мили
- Riddle Memorial Hospital, Media · на 12 мили
- Paoli Memorial Hospital, Paoli · на 18 мили
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
- Jefferson Hospital Northeast, Philadelphia
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Набиране на участнициФаза 3
- Local Institution - 0504, Philadelphia
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
Набиране на участнициНаблюдателно проучване
- Lankenau Medical Center, Paoli · на 18 мили
An External Control Arm Study in Non-Small Cell Lung Cancer
Набиране на участнициНаблюдателно проучване
- Main Line Health, Wynnewood · на 7 мили
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Набиране на участнициФаза 2/3
- Hospital of the University of Pennsylvania, Philadelphia
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Набиране на участнициФаза 3
- Clinical Study Site, Philadelphia
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Набиране на участнициНаблюдателно проучване
- University of Pennsylvania, Philadelphia
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Набиране на участнициФаза 3
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
- USO - Alliance Cancer Specialists, PC, Horsham · на 16 мили
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Набиране на участнициФаза 3
- Thomas Jefferson University - Clinical Research Institute ( Site 0147), Philadelphia
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Набиране на участнициФаза 1/2
- Thomas Jefferson University Research Facility, Philadelphia
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Набиране на участнициФаза 1
- Thomas Jefferson University, Philadelphia
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Набиране на участнициФаза 3
- Fox Chase Cancer Center, Philadelphia
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Набиране на участнициНаблюдателно проучване
- Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Набиране на участнициФаза 1/2
- Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Набиране на участнициФаза 1
- Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Набиране на участнициФаза 2
- Abramson Cancer Center ( Site 0010), Philadelphia
TCR1188-ABC Cells in KRAS-mutated Cancers
Набиране на участнициФаза 1
- University of Pennsylvania, Philadelphia
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Набиране на участнициФаза 1/2
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- Thomas Jefferson University, Philadelphia
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Набиране на участнициФаза 1
- Jefferson University Hospitals, Philadelphia
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Набиране на участнициФаза 1/2
- Fox Chase Cancer Center, Philadelphia
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Набиране на участнициФаза 3
- Thomas Jefferson University Hospital, Philadelphia
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Набиране на участнициФаза 3
- Abramson Cancer Center, Philadelphia
MOv19-BBz CAR T Cells in FRa+ Cancers
Набиране на участнициФаза 1
- University of Pennsylvania, Philadelphia
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Набиране на участнициФаза 2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Набиране на участнициФаза 1
- Perelman Center for Advanced Medicine /ID# 250188, Philadelphia
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- UPMC Hillman Cancer Center - Part of Frick Hospital, Mount Pleasant · на 8 мили
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Набиране на участнициФаза 2
- Fox Chase Cancer Center, Philadelphia
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2/3
- Fox Chase Cancer Center, Philadelphia
- Temple University Hospital, Philadelphia
- UPMC Hillman Cancer Center - Part of Frick Hospital, Mount Pleasant · на 8 мили
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Набиране на участнициФаза 2
- Fox Chase Cancer Center, Philadelphia
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Набиране на участнициФаза 1/2
- Univ of Pennsylvania, Abramson Cancer Center, Philadelphia
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
Набиране на участнициФаза 2
- University of Pennsylvania, Philadelphia
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- Fox Chase Cancer Center, Philadelphia
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Набиране на участнициФаза 1/2
- University of Pennsylvania, Philadelphia
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- University of Pennsylvania, Philadelphia
The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
Набиране на участници
- Jefferson Health Northeast, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
- Abington Memorial Hospital, Abington · на 12 мили
- и още 1
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Набиране на участнициФаза 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набиране на участнициНаблюдателно проучване
- Massive Bio SYNERGY-AI site, Philadelphia
Проучвания за Рак на белия дроб с недребноклетъчен тип в други градове
- Houston, TX145 проучвания
- New York City, NY121 проучвания
- Arlington, VA104 проучвания
- Nashville, TN97 проучвания
- Boston, MA90 проучвания
- Los Angeles, CA87 проучвания
- St. Louis, MO73 проучвания
- Chicago, IL61 проучвания
- Baltimore, MD60 проучвания
- San Antonio, TX59 проучвания
- Columbus, OH57 проучвания
- Washington, DC55 проучвания
Други проучвания в Philadelphia
- Рак (всички видове)59 проучвания
- Рак на гърдата56 проучвания
- Метастатичен рак46 проучвания
- Рак на простатата44 проучвания
- Колоректален рак44 проучвания
- Рак на яйчниците44 проучвания
- Рак на белия дроб36 проучвания
- Остра миелоидна левкемия34 проучвания
- Сърдечна недостатъчност31 проучвания
- Ендометриален рак28 проучвания
- Депресия26 проучвания
- Рак на панкреаса26 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.